BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 26, 2009
View Archived Issues
Novel ligand-directed toxin EGF4KDEL 7mut shows promise in preclinical cancer models
Read More
Shire reports results from third quarter of 2009
Read More
Phase III data support benefit of mipomersen in homozygous familiar hypercholesterolemia
Read More
Aleglitazar has no clinically relevant interactions with statins in healthy subjects
Read More
Opioid-nornicotine co-drugs described by the University of Kentucky
Read More
CytRx to initiate phase II INNO-206 trial in patients with soft tissue sarcomas
Read More
Cytopia begins enrollment in phase I/II trial of CYT-387 in myelofibrosis
Read More
Clinical data support safety of mepolizumab in pediatric eosinophilic esophagitis
Read More
Gilead Sciences and GSK sign licensing agreement to commercialize Viread for HBV in Asia
Read More
Novel dipeptidyl peptidase-IV inhibitors in early development at Sun Pharma
Read More
FDA reviews preliminary data from SCOUT safety study of Meridia
Read More
Cylene Pharmaceuticals claims novel protein kinase inhibitors for cancer treatment
Read More
Nycomed discovers PDE5A inhibitors for the treatment of asthma
Read More
Actelion claims P2Y12 receptor antagonists
Read More
Transcept to meet with FDA to discuss complete response letter on Intermezzo for insomnia
Read More
Accelerate Brain Cancer Cure awards grant to Tocagen to develop treatment for recurrent GBM
Read More
Proteon begins phase I/II trial of PRT-201 for improvement of vascular access in ESRD
Read More
Ipsen initiates phase II trial of BN-83495 in endometrial cancer
Read More
FDA accepts for review Eisai's Aricept NDA for moderate to severe AD
Read More
Preclinical characterization of PKI-402 disclosed at AACR-NCI-EORTC meeting
Read More
Correlation between high TNFalpha levels and tumor susceptibility to LCL-161
Read More
Aegera Therapeutics begins phase IIb AEG-35156 study in acute myeloid leukemia
Read More
Astex Therapeutics' AT-9283 is granted orphan drug status in AML in U.S. and Europe
Read More
Human Genome Sciences submits BLA to FDA for Zalbin to treat hepatitis C
Read More
Merck & Co. and Idera extend research collaboration on TLR agonist vaccine adjuvants
Read More
Agensys and Seattle Genetics expand antibody-drug conjugate collaboration
Read More